Clinical Trial Update: Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring rituximab combined with telitacicept for ANCA-associated vasculitis, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• Rituximab (rituximab)
• Telitacicept

Snippet

Sponsor: Chinese SLE Treatment And Research Group | Conditions: ANCA Associated Vasculitis | Phase 4 | Status: RECRUITING